Entera Bio Ltd.
For the period ended Jul 16, 2025. Filed Jul 18, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jul 16, 2025 · Filed Jul 18, 2025
Use the contents to explore the available documents and sections.
Contents
PROXY STATEMENT
Proxy Statement on Schedule 14A (the “Proxy Statement”) filed with the Securities and Exchange Commission on June 5, 2025, in connection with the Annual Meeting, relating to Ms. Miranda Toledano, the Company’s Chief Executive Officer and a Director:
| Votes · Votes · Broker | |||
|---|---|---|---|
| For | Against | Abstentions | Non-Votes |
| 19,524,783 | 428,993 | 542,191 | 6,197,026 |
Proposal 3: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy Statement, relating to Dr. Gregory Burshtein, the Company’s Chief of Research & Development:
| Votes · Votes · Broker | |||
|---|---|---|---|
| For | Against | Abstentions | Non-Votes |
| 16,518,134 | 3,435,638 | 542,195 | 6,197,026 |
Proposal 4: Ratification and approval of revised compensation terms and a one-time grant of compensation, as described in the Proxy Statement, relating to Ms. Dana Yaacov-Garbeli, the Company’s Chief Financial Officer:
| Votes · Votes · Broker | |||
|---|---|---|---|
| For | Against | Abstentions | Non-Votes |
| 19,524,779 | 428,993 | 542,195 | 6,197,026 |
Proposal 5: Ratification and approval of the Company’s amended and restated compensation policy for the directors and officers of the Company, as described in the Proxy Statement:
| Votes · Votes · Broker | |||
|---|---|---|---|
| For | Against | Abstentions | Non-Votes |
| 19,520,049 | 432,623 | 543,295 | 6,197,026 |
Proposal 6: Ratification and approval, on an advisory, non-binding basis, of the compensation of the Company’s named executive officers, as described in the Proxy Statement:
| Votes · Votes · Broker | |||
|---|---|---|---|
| For | Against | Abstentions | Non-Votes |
| 19,508,920 | 443,752 | 543,295 | 6,197,026 |
Proposal 7: Ratification and approval of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2025, andauthorization of the Company’s Board of Directors, or the
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.